News

Vanda president and CEO Mihael Polymeropoulos said: "The MAA validation demonstrates Vanda’s commitment to offer another option to the healthcare community to treat a severe, disabling mental disorder.

In the pivotal clinical trial, rVIII-SingleChain met all primary endpoints. Hemophilia A is a congenital bleeding disorder characterized by deficient or defective factor VIII; nearly all affected patients

T2D is a chronic syndrome that is caused due to dysregulation of blood sugar levels. The research collaboration is expected to address underlying pathologies of diabetes, which is

Under the Javelin Ovarian 200 open-label, parallel group, global study, the companies will assess the superiority of avelumab as monotherapy or in combination with pegylated liposomal doxorubicin (PLD)

The research will focus on using Emulate’s Small Airway Lung-Chip and Intestine-Chip to enable predictive modeling of inflammatory processes in the human lung and the gastrointestinal system. The

Abivax CEO Hartmut Ehrlich said: "ABX464 is a first-in-class antiviral drug candidate for the treatment of patients with HIV-infection. It is an orally available small molecule inhibiting HIV

CCP-07 is the second product being developed for Vernalis by Tris Pharma Inc ("Tris") for the US prescription cough cold market. The first product, TuzistraXR was approved by

The company is investing KRW850bn ($723m) in the new plant, which will boast a production capacity of 180,000 liters to become the single largest biologics manufacturing facility in

Medidata’s technology platform will allow the pharmaceutical firm to carry out faster and more accurate clinical trials. The study planning, data management, data analytics and risk-based monitoring (RBM)